🚀 VC round data is live in beta, check it out!
Vanda Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Vanda Pharmaceuticals and similar public comparables like Eupraxia Pharmaceuticals, Ovid Therapeutics, Shanghai Hile Bio-Tech, Aura Biosciences and more.
Vanda Pharmaceuticals Overview
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Founded
2002
HQ
Employees
533
Website
Sectors
Financials (LTM)
EV
$182M
Vanda Pharmaceuticals Financials
Vanda Pharmaceuticals reported last 12-month revenue of $227M.
In the same LTM period, Vanda Pharmaceuticals generated $213M in gross profit and had net loss of ($197M).
Revenue (LTM)
Vanda Pharmaceuticals P&L
In the most recent fiscal year, Vanda Pharmaceuticals reported revenue of $216M and EBITDA of ($139M).
Vanda Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $227M | XXX | $216M | XXX | XXX | XXX |
| Gross Profit | $213M | XXX | $203M | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | 94% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($139M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (64%) | XXX | XXX | XXX |
| EBIT Margin | (67%) | XXX | (70%) | XXX | XXX | XXX |
| Net Profit | ($197M) | XXX | ($220M) | XXX | XXX | XXX |
| Net Margin | (87%) | XXX | (102%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Vanda Pharmaceuticals Stock Performance
Vanda Pharmaceuticals has current market cap of $433M, and enterprise value of $182M.
Market Cap Evolution
Vanda Pharmaceuticals' stock price is $7.33.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $182M | $433M | 0.5% | XXX | XXX | XXX | $-3.73 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVanda Pharmaceuticals Valuation Multiples
Vanda Pharmaceuticals trades at 0.8x EV/Revenue multiple, and (1.3x) EV/EBITDA.
EV / Revenue (LTM)
Vanda Pharmaceuticals Financial Valuation Multiples
As of April 11, 2026, Vanda Pharmaceuticals has market cap of $433M and EV of $182M.
Equity research analysts estimate Vanda Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vanda Pharmaceuticals has a P/E ratio of (2.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $433M | XXX | $433M | XXX | XXX | XXX |
| EV (current) | $182M | XXX | $182M | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.3x) | XXX | XXX | XXX |
| EV/EBIT | (1.2x) | XXX | (1.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| P/E | (2.2x) | XXX | (2.0x) | XXX | XXX | XXX |
| EV/FCF | (1.6x) | XXX | (1.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Vanda Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Vanda Pharmaceuticals Margins & Growth Rates
Vanda Pharmaceuticals' revenue in the last 12 month grew by 25%.
Vanda Pharmaceuticals' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.7M for the same period.
Vanda Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 25% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (64%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 328% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 50% | XXX | 51% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 164% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Vanda Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Eupraxia Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Ovid Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Shanghai Hile Bio-Tech | XXX | XXX | XXX | XXX | XXX | XXX |
| Aura Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Emergent BioSolutions | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vanda Pharmaceuticals M&A Activity
Vanda Pharmaceuticals acquired XXX companies to date.
Last acquisition by Vanda Pharmaceuticals was on XXXXXXXX, XXXXX. Vanda Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Vanda Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVanda Pharmaceuticals Investment Activity
Vanda Pharmaceuticals invested in XXX companies to date.
Vanda Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Vanda Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Vanda Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Vanda Pharmaceuticals
| When was Vanda Pharmaceuticals founded? | Vanda Pharmaceuticals was founded in 2002. |
| Where is Vanda Pharmaceuticals headquartered? | Vanda Pharmaceuticals is headquartered in United States. |
| How many employees does Vanda Pharmaceuticals have? | As of today, Vanda Pharmaceuticals has over 533 employees. |
| Who is the CEO of Vanda Pharmaceuticals? | Vanda Pharmaceuticals' CEO is Mihael Hristos Polymeropoulos. |
| Is Vanda Pharmaceuticals publicly listed? | Yes, Vanda Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Vanda Pharmaceuticals? | Vanda Pharmaceuticals trades under VNDA ticker. |
| When did Vanda Pharmaceuticals go public? | Vanda Pharmaceuticals went public in 2006. |
| Who are competitors of Vanda Pharmaceuticals? | Vanda Pharmaceuticals main competitors are Eupraxia Pharmaceuticals, Ovid Therapeutics, Shanghai Hile Bio-Tech, Aura Biosciences. |
| What is the current market cap of Vanda Pharmaceuticals? | Vanda Pharmaceuticals' current market cap is $433M. |
| What is the current revenue of Vanda Pharmaceuticals? | Vanda Pharmaceuticals' last 12 months revenue is $227M. |
| What is the current revenue growth of Vanda Pharmaceuticals? | Vanda Pharmaceuticals revenue growth (NTM/LTM) is 25%. |
| What is the current EV/Revenue multiple of Vanda Pharmaceuticals? | Current revenue multiple of Vanda Pharmaceuticals is 0.8x. |
| Is Vanda Pharmaceuticals profitable? | No, Vanda Pharmaceuticals is not profitable. |
| What is the current net income of Vanda Pharmaceuticals? | Vanda Pharmaceuticals' last 12 months net income is ($197M). |
| What is the current FCF of Vanda Pharmaceuticals? | Vanda Pharmaceuticals' last 12 months FCF is ($113M). |
| What is Vanda Pharmaceuticals' FCF margin? | Vanda Pharmaceuticals' last 12 months FCF margin is (50%). |
| What is the current EV/FCF multiple of Vanda Pharmaceuticals? | Current FCF multiple of Vanda Pharmaceuticals is (1.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.